Cargando…

Intensity modulated radiotherapy in early stage Hodgkin lymphoma patients: Is it better than three dimensional conformal radiotherapy?

BACKGROUND: Cure rate of early Hodgkin Lymphoma are high and avoidance of late toxicities is of paramount importance. This comparative study aims to assess the normal tissue sparing capability of intensity-modulated radiation therapy (IMRT) versus standard three-dimensional conformal radiotherapy (3...

Descripción completa

Detalles Bibliográficos
Autores principales: De Sanctis, Vitaliana, Bolzan, Chiara, D’Arienzo, Marco, Bracci, Stefano, Fanelli, Alessandro, Cox, Maria Christina, Valeriani, Maurizio, Osti, Mattia F, Minniti, Giuseppe, Chiacchiararelli, Laura, Enrici, Riccardo Maurizi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3484070/
https://www.ncbi.nlm.nih.gov/pubmed/22857015
http://dx.doi.org/10.1186/1748-717X-7-129
_version_ 1782248094562254848
author De Sanctis, Vitaliana
Bolzan, Chiara
D’Arienzo, Marco
Bracci, Stefano
Fanelli, Alessandro
Cox, Maria Christina
Valeriani, Maurizio
Osti, Mattia F
Minniti, Giuseppe
Chiacchiararelli, Laura
Enrici, Riccardo Maurizi
author_facet De Sanctis, Vitaliana
Bolzan, Chiara
D’Arienzo, Marco
Bracci, Stefano
Fanelli, Alessandro
Cox, Maria Christina
Valeriani, Maurizio
Osti, Mattia F
Minniti, Giuseppe
Chiacchiararelli, Laura
Enrici, Riccardo Maurizi
author_sort De Sanctis, Vitaliana
collection PubMed
description BACKGROUND: Cure rate of early Hodgkin Lymphoma are high and avoidance of late toxicities is of paramount importance. This comparative study aims to assess the normal tissue sparing capability of intensity-modulated radiation therapy (IMRT) versus standard three-dimensional conformal radiotherapy (3D-CRT) in terms of dose-volume parameters and normal tissue complication probability (NTCP) for different organs at risk in supradiaphragmatic Hodgkin Lymphoma (HL) patients. METHODS: Ten HL patients were actually treated with 3D-CRT and all treatments were then re-planned with IMRT. Dose-volume parameters for thyroid, oesophagus, heart, coronary arteries, lung, spinal cord and breast were evaluated. Dose-volume histograms generated by TPS were analyzed to predict the NTCP for the considered organs at risk, according to different endpoints. RESULTS: Regarding dose-volume parameters no statistically significant differences were recorded for heart and origin of coronary arteries. We recorded statistically significant lower V30 with IMRT for oesophagus (6.42 vs 0.33, p = 0.02) and lungs (4.7 vs 0.1 p = 0.014 for the left lung and 2.59 vs 0.1 p = 0.017 for the right lung) and lower V20 for spinal cord (17.8 vs 7.2 p = 0.02). Moreover the maximum dose to the spinal cord was lower with IMRT (30.2 vs 19.9, p <0.001). Higher V10 with IMRT for thyroid (64.8 vs 95, p = 0.0019) and V5 for lungs (30.3 vs 44.8, p = 0.03, for right lung and 28.9 vs 48.1, p = 0.001 for left lung) were found, respectively. Higher V5 and V10 for breasts were found with IMRT (V5: 4.14 vs 20.6, p = 0.018 for left breast and 3.3 vs 17, p = 0.059 for right breast; V10: 2.5 vs 13.6 p = 0.035 for left breast and 1.7 vs 11, p = 0.07 for the right breast.) As for the NTCP, our data point out that IMRT is not always likely to significantly increase the NTCP to OARs. CONCLUSIONS: In HL male patients IMRT seems feasible and accurate while for women HL patients IMRT should be used with caution.
format Online
Article
Text
id pubmed-3484070
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34840702012-11-05 Intensity modulated radiotherapy in early stage Hodgkin lymphoma patients: Is it better than three dimensional conformal radiotherapy? De Sanctis, Vitaliana Bolzan, Chiara D’Arienzo, Marco Bracci, Stefano Fanelli, Alessandro Cox, Maria Christina Valeriani, Maurizio Osti, Mattia F Minniti, Giuseppe Chiacchiararelli, Laura Enrici, Riccardo Maurizi Radiat Oncol Research BACKGROUND: Cure rate of early Hodgkin Lymphoma are high and avoidance of late toxicities is of paramount importance. This comparative study aims to assess the normal tissue sparing capability of intensity-modulated radiation therapy (IMRT) versus standard three-dimensional conformal radiotherapy (3D-CRT) in terms of dose-volume parameters and normal tissue complication probability (NTCP) for different organs at risk in supradiaphragmatic Hodgkin Lymphoma (HL) patients. METHODS: Ten HL patients were actually treated with 3D-CRT and all treatments were then re-planned with IMRT. Dose-volume parameters for thyroid, oesophagus, heart, coronary arteries, lung, spinal cord and breast were evaluated. Dose-volume histograms generated by TPS were analyzed to predict the NTCP for the considered organs at risk, according to different endpoints. RESULTS: Regarding dose-volume parameters no statistically significant differences were recorded for heart and origin of coronary arteries. We recorded statistically significant lower V30 with IMRT for oesophagus (6.42 vs 0.33, p = 0.02) and lungs (4.7 vs 0.1 p = 0.014 for the left lung and 2.59 vs 0.1 p = 0.017 for the right lung) and lower V20 for spinal cord (17.8 vs 7.2 p = 0.02). Moreover the maximum dose to the spinal cord was lower with IMRT (30.2 vs 19.9, p <0.001). Higher V10 with IMRT for thyroid (64.8 vs 95, p = 0.0019) and V5 for lungs (30.3 vs 44.8, p = 0.03, for right lung and 28.9 vs 48.1, p = 0.001 for left lung) were found, respectively. Higher V5 and V10 for breasts were found with IMRT (V5: 4.14 vs 20.6, p = 0.018 for left breast and 3.3 vs 17, p = 0.059 for right breast; V10: 2.5 vs 13.6 p = 0.035 for left breast and 1.7 vs 11, p = 0.07 for the right breast.) As for the NTCP, our data point out that IMRT is not always likely to significantly increase the NTCP to OARs. CONCLUSIONS: In HL male patients IMRT seems feasible and accurate while for women HL patients IMRT should be used with caution. BioMed Central 2012-08-02 /pmc/articles/PMC3484070/ /pubmed/22857015 http://dx.doi.org/10.1186/1748-717X-7-129 Text en Copyright ©2012 De Sanctis et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
De Sanctis, Vitaliana
Bolzan, Chiara
D’Arienzo, Marco
Bracci, Stefano
Fanelli, Alessandro
Cox, Maria Christina
Valeriani, Maurizio
Osti, Mattia F
Minniti, Giuseppe
Chiacchiararelli, Laura
Enrici, Riccardo Maurizi
Intensity modulated radiotherapy in early stage Hodgkin lymphoma patients: Is it better than three dimensional conformal radiotherapy?
title Intensity modulated radiotherapy in early stage Hodgkin lymphoma patients: Is it better than three dimensional conformal radiotherapy?
title_full Intensity modulated radiotherapy in early stage Hodgkin lymphoma patients: Is it better than three dimensional conformal radiotherapy?
title_fullStr Intensity modulated radiotherapy in early stage Hodgkin lymphoma patients: Is it better than three dimensional conformal radiotherapy?
title_full_unstemmed Intensity modulated radiotherapy in early stage Hodgkin lymphoma patients: Is it better than three dimensional conformal radiotherapy?
title_short Intensity modulated radiotherapy in early stage Hodgkin lymphoma patients: Is it better than three dimensional conformal radiotherapy?
title_sort intensity modulated radiotherapy in early stage hodgkin lymphoma patients: is it better than three dimensional conformal radiotherapy?
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3484070/
https://www.ncbi.nlm.nih.gov/pubmed/22857015
http://dx.doi.org/10.1186/1748-717X-7-129
work_keys_str_mv AT desanctisvitaliana intensitymodulatedradiotherapyinearlystagehodgkinlymphomapatientsisitbetterthanthreedimensionalconformalradiotherapy
AT bolzanchiara intensitymodulatedradiotherapyinearlystagehodgkinlymphomapatientsisitbetterthanthreedimensionalconformalradiotherapy
AT darienzomarco intensitymodulatedradiotherapyinearlystagehodgkinlymphomapatientsisitbetterthanthreedimensionalconformalradiotherapy
AT braccistefano intensitymodulatedradiotherapyinearlystagehodgkinlymphomapatientsisitbetterthanthreedimensionalconformalradiotherapy
AT fanellialessandro intensitymodulatedradiotherapyinearlystagehodgkinlymphomapatientsisitbetterthanthreedimensionalconformalradiotherapy
AT coxmariachristina intensitymodulatedradiotherapyinearlystagehodgkinlymphomapatientsisitbetterthanthreedimensionalconformalradiotherapy
AT valerianimaurizio intensitymodulatedradiotherapyinearlystagehodgkinlymphomapatientsisitbetterthanthreedimensionalconformalradiotherapy
AT ostimattiaf intensitymodulatedradiotherapyinearlystagehodgkinlymphomapatientsisitbetterthanthreedimensionalconformalradiotherapy
AT minnitigiuseppe intensitymodulatedradiotherapyinearlystagehodgkinlymphomapatientsisitbetterthanthreedimensionalconformalradiotherapy
AT chiacchiararellilaura intensitymodulatedradiotherapyinearlystagehodgkinlymphomapatientsisitbetterthanthreedimensionalconformalradiotherapy
AT enriciriccardomaurizi intensitymodulatedradiotherapyinearlystagehodgkinlymphomapatientsisitbetterthanthreedimensionalconformalradiotherapy